Login to Your Account



Santhera's Stock Plummets on Idebenone Phase III Miss

By Cormac Sheridan


Wednesday, May 27, 2009
Shares in Santhera Pharmaceuticals Holding AG plunged 40 percent last week on news that its lead compound Catena (idebenone) missed the primary endpoint in a U.S. Phase III trial in patients with Friedreich's Ataxia. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription